Ann: Phase 2 trial shows significant improvements in Angelman, page-58

Jon addressed my question at the end. It seems they are already talking to Big Pharma but nothing firm until the FDA meeting.

Partnering was not an option (my take on it which is great in my opinion).

Postering by saying we can potentially take 2 indications to phase 3 approval. If Big Pharma want it prior they need to pay up.

In addition, knowing NEU they would prefer a take out to include Big Pharma progressing with more than 2 indications ASAP to get it to the patients.

I feel a take out versus progressing 2 indications all the way to phase 3 is 60:40.

IMO, DYOR